Business
OrthoPediatrics Corp. Reports First Quarter 2025 Financial Results and Increases Full Year 2025 Revenue Guidance
First Quarter 2025 Revenue Increased 17% Year-over-YearWARSAW, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the first quarter ended March 31, 2025. First Quarter 2025 and Business Highlights Helped a record of nearly 39,000 children in the first quarter of 2025Generated total revenue of $52.4 million for the
About this update from Orthopediatrics Corp.
[{"type":"image","alt":"OrthoPediatrics Corp.","displaySize":"","headline":null,"caption":"OrthoPediatrics Corp.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":96,"url":"https://media.zenfs.com/en/globenewswire.com/29d424390c1c4ef384b72b889c10210b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1WUGYhT71wCcQ7.AD2ziQQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/29d424390c1c4ef384b72b889c10210b","width":300,"height":96}},"lazy":false},{"type":"text","content":"First Quarter 2025 Revenue Increased 17% Year-over-Year","length":55,"tagName":"p"},{"type":"text","content":"WARSAW, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the first quarter ended March 31, 2025.","length":287,"tagName":"p"},{"type":"text","content":"First Quarter 2025 and Business Highlights","length":42,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Helped a record of nearly 39,000 children in the first quarter of 2025","length":70,"tagName":"p"}]},{"val":[{"type":"text","content":"Generated total revenue of $52.4 million for the first quarter of 2025, up 17% from $44.7 million in first quarter 2024; domestic revenue increased 19% and international revenue increased 11% in the quarter","length":206,"tagName":"p"}]},{"val":[{"type":"text","content":"Grew worldwide Trauma & Deformity revenue 14% and worldwide Scoliosis revenue 34% in the first quarter of 2025 compared to the first quarter of 2024","length":152,"tagName":"p"}]},{"val":[{"type":"text","content":"Achieved adjusted EBITDA of ($0.4) million in the first quarter of 2025, compared to ($1.1) million in the first quarter of 2024","length":128,"tagName":"p"}]},{"val":[{"type":"text","content":"Reduced first quarter 2025 free cash flow usage by 35% as compared to the same period in the prior year. Anticipate first full quarter of positive free cash flow in fourth quarter 2025","length":184,"tagName":"p"}]},{"val":[{"type":"text","content":"Expanded scoliosis portfolio with the launch of VerteGlide™ System, used to treat Early Onset Scoliosis (“EOS”), marking the Company's 80th system brought to market","length":168,"tag...